91 related articles for article (PubMed ID: 21779912)
1. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction.
Prasad KM; Smith RS; Xu Y; French BA
J Gene Med; 2011 Jun; 13(6):333-41. PubMed ID: 21674736
[TBL] [Abstract][Full Text] [Related]
2. Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials.
Schulz M; Bashirians G; Cheng SH; Levy DI; Lundie M; Wilcox L; Winburn I; Somanathan S
Mol Ther Methods Clin Dev; 2023 Dec; 31():101119. PubMed ID: 37868207
[No Abstract] [Full Text] [Related]
3. A year later.
Correia MITD
Rev Col Bras Cir; 2021; 48():e2021EDIT01. PubMed ID: 33729320
[No Abstract] [Full Text] [Related]
4. Single dose of synthetic microRNA-199a or microRNA-149 mimic does not improve cardiac function in a murine model of myocardial infarction.
Nong Y; Guo Y; Gumpert A; Li Q; Tomlin A; Zhu X; Bolli R
Mol Cell Biochem; 2021 Nov; 476(11):4093-4106. PubMed ID: 34287784
[TBL] [Abstract][Full Text] [Related]
5. Preconditioning c-Kit-positive Human Cardiac Stem Cells with a Nitric Oxide Donor Enhances Cell Survival through Activation of Survival Signaling Pathways.
Teng L; Bennett E; Cai C
J Biol Chem; 2016 Apr; 291(18):9733-47. PubMed ID: 26940876
[TBL] [Abstract][Full Text] [Related]
6. Recruitment and retention of human autologous CD34+ CD117+ CD133+ bone marrow stem cells to infarcted myocardium followed by directed vasculogenesis: Novel strategy for cardiac regeneration.
Malecki M; Sabo C; Putzer E; Stampe C; Foorohar A; Quach C; Beauchaine M; Tombokan X; Anderson M
Mol Cell Ther; 2013 Dec; 1():. PubMed ID: 25045527
[TBL] [Abstract][Full Text] [Related]
7. Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion.
Obal D; Dai S; Keith R; Dimova N; Kingery J; Zheng YT; Zweier J; Velayutham M; Prabhu SD; Li Q; Conklin D; Yang D; Bhatnagar A; Bolli R; Rokosh G
Basic Res Cardiol; 2012 Nov; 107(6):305. PubMed ID: 23099819
[TBL] [Abstract][Full Text] [Related]
8. Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice.
Guo Y; Flaherty MP; Wu WJ; Tan W; Zhu X; Li Q; Bolli R
Basic Res Cardiol; 2012 Sep; 107(5):288. PubMed ID: 22864681
[TBL] [Abstract][Full Text] [Related]
9. The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning.
Guo Y; Tukaye DN; Wu WJ; Zhu X; Book M; Tan W; Jones SP; Rokosh G; Narumiya S; Li Q; Bolli R
PLoS One; 2012; 7(7):e41178. PubMed ID: 22844439
[TBL] [Abstract][Full Text] [Related]
10. Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury.
Guo Y; Sanganalmath SK; Wu W; Zhu X; Huang Y; Tan W; Ildstad ST; Li Q; Bolli R
Basic Res Cardiol; 2012 Mar; 107(2):253. PubMed ID: 22351077
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.
Li Q; Guo Y; Tan W; Stein AB; Dawn B; Wu WJ; Zhu X; Lu X; Xu X; Siddiqui T; Tiwari S; Bolli R
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H584-9. PubMed ID: 16172153
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.
Li Q; Guo Y; Xuan YT; Lowenstein CJ; Stevenson SC; Prabhu SD; Wu WJ; Zhu Y; Bolli R
Circ Res; 2003 Apr; 92(7):741-8. PubMed ID: 12702642
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.
Bolli R
J Mol Cell Cardiol; 2001 Nov; 33(11):1897-918. PubMed ID: 11708836
[TBL] [Abstract][Full Text] [Related]
14. Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction.
Xi L; Kukreja RC
Toxicology; 2000 Nov; 155(1-3):37-44. PubMed ID: 11154795
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.
Li Q; Guo Y; Wu WJ; Ou Q; Zhu X; Tan W; Yuan F; Chen N; Dawn B; Luo L; O'Brien E; Bolli R
Basic Res Cardiol; 2011 Nov; 106(6):1355-66. PubMed ID: 21779912
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.
Li Q; Guo Y; Ou Q; Wu WJ; Chen N; Zhu X; Tan W; Yuan F; Dawn B; Luo L; Hunt GN; Bolli R
Basic Res Cardiol; 2011 Nov; 106(6):1367-77. PubMed ID: 21785893
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
